REFERENCE · RECOVERY TECHNIQUE
Discussing Botulinum Toxin With a Specialist
Home › Recovery Techniques › Functional Facial Symptoms
When this may fit: When a specialist proposes an injection for a specific facial pattern or a coexisting movement disorder. [Uncertain selected use; evidence does not support routine injection for functional facial symptoms]
For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources
—
For the Person With FND
An injection can sound appealing when pulling has become painful or exhausting. You deserve a clear explanation of what it is meant to treat, what benefit is realistic and what could become harder afterward.
What does botulinum toxin do?
Botulinum toxin, sometimes called Botox after one brand, temporarily reduces nerve signals to an injected muscle. This weakens its contraction. It does not directly treat every process involved in FND. Its use for another condition, such as some facial-nerve problems, is a different indication. [1]
Why the advice is cautious
Facial specialist guidance reports little apparent benefit for typical functional facial spasm. Retrospective facial and jaw/mouth studies describe improvement in some selected patients, but without an appropriate control group these observations cannot establish an injection effect. [2] [3] [4]
A small randomized trial in persistent functional dystonia found no added benefit of toxin over placebo before cognitive behavioural therapy. It was not a facial-specific trial and was too small to settle every possible selected use. Taken together, these findings do not support routine injection simply because a functional facial movement is visible. [5]
Questions for the specialist
- What exact problem are you treating, and is another diagnosis present?
- What practical goal are we aiming for: pain relief, easier care or another function?
- Why is weakening these muscles expected to help rather than impair speaking, chewing or eye protection?
- What alternatives are available, including continuing support without injection?
- When will we assess benefit and harm, and what would make us stop further injections?
A written plan should include how to contact the service and what symptoms require urgent help. You can take time to decide; declining an injection does not mean declining recovery.
What could go wrong?
Depending on the treated area, adverse effects can include bruising, unwanted facial weakness, eyelid droop or difficulty with speech and swallowing. Breathing or swallowing difficulty after injection needs urgent assessment; follow the service’s emergency instructions. [1]
Do not seek cosmetic injection as a substitute for an assessment of functional symptoms. Surgery is not an established routine treatment for functional facial symptoms. A separately diagnosed dental, nerve or eye condition may have its own indication, which should be explained separately. [6]
During a familiar flare, use your care plan and contact the treating team if needed. Do not assume an extra injection is the next step. Whether an injection helps or not does not prove or disprove FND.
New or different symptoms: Sudden new facial droop or weakness, speech difficulty or other possible stroke symptoms need emergency assessment, even if they stop. Call your local emergency number; do not wait for an exercise to work. [7]
For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources
—
For Family, Friends, and Other Supporters
Support an informed choice without urging the person to accept a procedure because you want the face to look different. Help keep the agreed goals and contact instructions available if requested.
After treatment, take new functional difficulties seriously. Report benefit and harm in everyday terms rather than treating the outcome as a test of whether the original symptoms were real.
For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources
—
For Clinicians and the Care Team
Define phenotype and indication, distinguishing coexisting nonfunctional disease from selected symptomatic treatment of functional overactivity. Discuss uncontrolled cohort bias and the small negative add-on trial. Document oral/ocular function, informed consent, expected onset, outcome review and stopping criteria. Avoid using immediate response diagnostically or offering an escalating procedural pathway without evidence. No dosing or injection-site guidance is provided here.
For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources
—
Research and Sources
This page expands original entry 10, Botulinum toxin or other invasive treatment only after specialist review. Practical examples and questions are educational adaptations, not patient quotations or a reproduced treatment protocol.
The Vizcarra pilot randomized 14 people and had 10 completers; it found no added toxin benefit over placebo before CBT. Cohorts by Fasano and Yoshida are uncontrolled and cannot resolve selected facial efficacy. The UCLH source concerns facial palsy/synkinesis: it supports mechanism and adverse-effect counselling only, not FND treatment effectiveness.
| Citation | Source | What it supports and its limits | Figure |
|---|---|---|---|
| 1 | FND-CIT-0198 — University College London Hospitals NHS Foundation Trust. Complex Facial Clinic: botulinum toxin injections as part of the clinic treatment. Source. Accessed September 22, 2026. | Adjacent facial-palsy/synkinesis treatment and adverse-effect information; not evidence of efficacy for functional facial symptoms. | — |
| 2 | FND-CIT-0056 — Stone J. Functional facial symptoms. Neurosymptoms.org. Source. Accessed September 22, 2026. | Specialist patient education on facial patterns and treatment; not trial evidence. | — |
| 3 | FND-CIT-0052 — Fasano A, Valadas A, Bhatia KP, et al. Psychogenic facial movement disorders: clinical features and associated conditions. Movement Disorders. 2012;27:1544–1551. DOI. | Retrospective specialist cohort; describes facial presentations and uncontrolled treatment observations. Historical terminology is retained only in the title. | — |
| 4 | FND-CIT-0053 — Yoshida K. Clinical characteristics of functional movement disorders in the stomatognathic system. Frontiers in Neurology. 2020;11:123. DOI. | Single-centre retrospective mouth/jaw cohort; subjective treatment observations do not establish injection efficacy. | — |
| 5 | FND-CIT-0093 — Vizcarra JA, Lopez-Castellanos JR, Dwivedi AK, et al. OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: a pilot randomized clinical trial. Parkinsonism & Related Disorders. 2019;63:174–178. DOI. | Small persistent functional-dystonia trial; toxin did not add benefit over placebo before CBT. Not a facial-specific trial. | — |
| 6 | FND-CIT-0055 — Gros P, Bhatt H, Gilmour GS, Lidstone SC. Rehabilitation for functional dystonia: cases and review of the literature. Movement Disorders Clinical Practice. 2024;11:1018–1024. DOI. | Four cases, including one episodic facial presentation, and a literature review; no controlled facial protocol or component effect. | — |
| 7 | FND-CIT-0108 — NHS. Symptoms of a stroke. Source. Accessed September 22, 2026. | Emergency safety guidance; not an FND treatment study. | — |
Sources checked: September 22, 2026 · Movement-disorders, speech-language, eye-care, lived-experience and accessibility review pending
For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources
—